Didanosine

This classification denotes a reverse transcriptase inhibitor with the molecular formula C10H12N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K3GDH6OH08, chemically known as 2,3-dideoxyinosine & scd4(soluble recombinant protein) but generally known as didanosine, which bears US NIH Compound Identifier 50599. European Medicines Agency schedules Didanosine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07104MIG. The term DIDANOSINE is an International Non-Proprietary Name. World Health Organization schedules didanosine in its Anatomical Therapeutic Chemical (ATC) Classification. DIDANOSINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule didanosine under HS 29349990 and SITC 51579. As of Q4 2014, DIDANOSINE remains the US FDA Preferred Term for this commodity. Didanosine bears US NLM identifiers UMLS ID C0012133 and NCI Concept Code C431. SMILES: C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2NC=NC3=O.